Literature DB >> 22713791

Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.

Julien Ratelade1, A S Verkman.   

Abstract

Neuromyelitis optica (NMO) is an autoimmune 'aquaporinopathy' of the central nervous system that causes inflammatory demyelinating lesions primarily in spinal cord and optic nerve, leading to paralysis and blindness. NMO lesions show loss of aquaporin-4 (AQP4), GFAP and myelin, infiltration of granulocytes and macrophages, and perivascular deposition of activated complement. Most patients with NMO are seropositive for immunoglobulin autoantibodies (AQP4-IgG) against AQP4, the principal water channel of astrocytes. There is strong evidence that AQP4-IgG is pathogenic in NMO, probably by a mechanism involving complement-dependent astrocyte cytotoxicity, causing leukocyte infiltration, cytokine release and blood-brain barrier disruption, which leads to oligodendrocyte death, myelin loss and neuron death. Here, we review the evidence for this and alternative proposed NMO pathogenesis mechanisms, such as AQP4-IgG-induced internalization of AQP4 and glutamate transporters, complement-independent cell-mediated cytotoxicity, and AQP4-IgG inhibition of AQP4 water transport function. Based on the initiating pathogenic role of AQP4-IgG binding to astrocyte AQP4 in NMO, selective blocker therapies are under development in which AQP4-targeted monoclonal antibodies or small molecules block binding of AQP4-IgG to astrocytes and consequent downstream pathology.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22713791      PMCID: PMC3676174          DOI: 10.1016/j.biocel.2012.06.013

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  82 in total

Review 1.  A current view of the mammalian aquaglyceroporins.

Authors:  Aleksandra Rojek; Jeppe Praetorius; Jørgen Frøkiaer; Søren Nielsen; Robert A Fenton
Journal:  Annu Rev Physiol       Date:  2008       Impact factor: 19.318

2.  Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  T Misu; K Fujihara; A Kakita; H Konno; M Nakamura; S Watanabe; T Takahashi; I Nakashima; H Takahashi; Y Itoyama
Journal:  Brain       Date:  2007-04-02       Impact factor: 13.501

3.  Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica.

Authors:  S R Hinson; S J Pittock; C F Lucchinetti; S F Roemer; J P Fryer; T J Kryzer; V A Lennon
Journal:  Neurology       Date:  2007-10-10       Impact factor: 9.910

4.  Aquaporin-4 autoantibodies in a paraneoplastic context.

Authors:  Sean J Pittock; Vanda A Lennon
Journal:  Arch Neurol       Date:  2008-05

5.  Aquaporin-4 dynamics in orthogonal arrays in live cells visualized by quantum dot single particle tracking.

Authors:  Jonathan M Crane; Alfred N Van Hoek; William R Skach; A S Verkman
Journal:  Mol Biol Cell       Date:  2008-05-21       Impact factor: 4.138

Review 6.  Roles of aquaporin-3 in the epidermis.

Authors:  Mariko Hara-Chikuma; A S Verkman
Journal:  J Invest Dermatol       Date:  2008-06-12       Impact factor: 8.551

Review 7.  The spectrum of neuromyelitis optica.

Authors:  Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

8.  Impaired olfaction in mice lacking aquaporin-4 water channels.

Authors:  Daniel C Lu; Hua Zhang; Zsolt Zador; A S Verkman
Journal:  FASEB J       Date:  2008-05-29       Impact factor: 5.191

9.  Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment.

Authors:  Thierry Vincent; Philippe Saikali; Romain Cayrol; Alejandro D Roth; Amit Bar-Or; Alexandre Prat; Jack P Antel
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

10.  Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2.

Authors:  Shannon R Hinson; Shanu F Roemer; Claudia F Lucchinetti; James P Fryer; Thomas J Kryzer; Jayne L Chamberlain; Charles L Howe; Sean J Pittock; Vanda A Lennon
Journal:  J Exp Med       Date:  2008-10-06       Impact factor: 14.307

View more
  31 in total

1.  Targeting ion channels for the treatment of autoimmune neuroinflammation.

Authors:  Stefan Bittner; Sven G Meuth
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

2.  Stratification of astrocytes in healthy and diseased brain.

Authors:  Alexei Verkhratsky; Robert Zorec; Vladimir Parpura
Journal:  Brain Pathol       Date:  2017-09       Impact factor: 6.508

Review 3.  Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy.

Authors:  Thomas Tourdias; Vincent Dousset
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

4.  The cancer drug tamoxifen: a potential therapeutic treatment for spinal cord injury.

Authors:  Jutatip Guptarak; John E Wiktorowicz; Rovshan G Sadygov; Dragoslava Zivadinovic; Adriana A Paulucci-Holthauzen; Leoncio Vergara; Olivera Nesic
Journal:  J Neurotrauma       Date:  2013-12-11       Impact factor: 5.269

5.  Identification of a point mutation impairing the binding between aquaporin-4 and neuromyelitis optica autoantibodies.

Authors:  Francesco Pisani; Maria Grazia Mola; Laura Simone; Stefania Rosito; Domenico Alberga; Giuseppe Felice Mangiatordi; Gianluca Lattanzi; Orazio Nicolotti; Antonio Frigeri; Maria Svelto; Grazia Paola Nicchia
Journal:  J Biol Chem       Date:  2014-09-19       Impact factor: 5.157

6.  The complement and immunoglobulin levels in NMO patients.

Authors:  Ying Chen; Rui Li; Ai Ming Wu; Ya Qing Shu; Zheng Qi Lu; Xue Qiang Hu
Journal:  Neurol Sci       Date:  2013-07-24       Impact factor: 3.307

7.  Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.

Authors:  John Soltys; Yiting Liu; Alanna Ritchie; Scott Wemlinger; Kristin Schaller; Hannah Schumann; Gregory P Owens; Jeffrey L Bennett
Journal:  J Clin Invest       Date:  2019-04-08       Impact factor: 14.808

8.  Significant Association Between Fc Receptor-Like 3 Polymorphisms (-1901A>G and -658C>T) and Neuromyelitis Optica (NMO) Susceptibility in the Chinese Population.

Authors:  Xinling Wang; Tao Yu; Qichang Yan; Wei Wang; Nan Meng; Xuejiao Li; Yahong Luo
Journal:  Mol Neurobiol       Date:  2015-01-10       Impact factor: 5.590

9.  Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders.

Authors:  Ziyan Shi; Qin Zhang; Hongxi Chen; Xiaohui Miao; Ju Liu; Zhiyun Lian; Huiru Feng; Hongyu Zhou
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590

Review 10.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.